Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Botulinum toxin (BTX) demonstrates potential as a complementary therapy in managing chronic orofacial pain (OFP), but challenges in the standardization of protocols and indications remain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17219/dmp/200127 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FACIAL SYMMETRY ENHANCEMENT AND BRAIN NETWORK MODIFICATIONS IN FACIAL PALSY PATIENTS AFTER BOTULINUM TOXIN TYPE A TREATMENT.
Plast Reconstr Surg
August 2025
Division of Plastic Surgery, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, São Paulo - 05403-000, Brazil.
Intralesional Botulinum Toxin A for Keloid Treatment: A Review of Efficacy, Safety, and Clinical Applications.
Clin Cosmet Investig Dermatol
September 2025
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital, Bandung, Indonesia.
Background: Keloids are fibroproliferative disorders characterized by excessive scarring, functional impairment, and aesthetic concerns. Despite the availability of various treatments, recurrence rates remain high, highlighting the need for alternative therapies with favorable safety profiles. Botulinum toxin A (BTX-A) has emerged as a potential option for keloid treatment; however, its therapeutic role is still not fully elucidated.
View Article and Find Full Text PDFPerineural botulinum toxin in the management of post-traumatic headache: a case report.
Rev Esp Anestesiol Reanim (Engl Ed)
September 2025
Physical Medicine and Rehabilitation. Universidad del Valle, Cali, Colombia; Interventional Pain Management, Fundalivio, Cali, Colombia.
Post traumatic headache is a common condition that can be managed with pharmacologic interventions or analgesic procedures; however, most evidence is derived from patients with mild trauma, leaving a large gap with regard to patients with moderate or severe trauma who present complex pain. Botulinum toxin plays an increasingly important role in pain management. This neurotoxin acts on different receptors, ranging from TRPV1 (transient receptor potential vanilloid type 1) to CGRP (calcitonin gene-related peptide).
View Article and Find Full Text PDFIs the Botulinum Toxin Injection Into the Cricopharyngeal Sphincter Precipitate Laryngopharyngeal Reflux Symptoms in Patients With Retrograde Cricopharyngeal Dysfunction?
J Voice
September 2025
Department of Otolaryngology - Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.
Objective: To investigate the potential relationship between retrograde cricopharyngeal dysfunction (R-CPD) and laryngopharyngeal reflux disease (LPRD) at baseline and whether cricopharyngeal sphincter paralysis botulinum toxin injection (BTI) is associated with an increase of LPRD symptoms in treated R-CPD patients.
Methods: Patients with clinical diagnosis of R-CPD were prospectively recruited from two European hospitals. Controls included individuals unable to burp without troublesome symptoms (CT1) and healthy subjects able to burp (CT2).
A Pilot Study of Differences in Antibody Responses of Intradermal and Intramuscular Injections of Botulinum Toxin Type A.
Dermatol Ther (Heidelb)
September 2025
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Introduction: Botulinum toxin type A (BoNT/A) is commonly used for both medical and aesthetic purposes. However, approximately 3% of long-term recipients develop resistance, potentially due to antibody formation. Injection technique may influence immunogenicity, yet comparative data remain limited.
View Article and Find Full Text PDF